ATP + Eria Jarensis + L-Carnitine + MIC + Lidocaine + Benzyl Alcohol - Lipo-C FOCUS

1 Identity

Fixed-ratio multi-component article, presented as an injectable solution, and not fully definable: a nucleotide triphosphate, a botanical extract of undefined composition, a zwitterionic quaternary ammonium acid, three further small molecules under the MIC abbreviation, an aminoamide drug substance that is the subject of a USP monograph, and an antimicrobial preservative excipient. No peptide bond anywhere in the article. L-Carnitine has its own record; the extract cannot have one.

Sequence

Not applicable to any component; there is no sequence in this article and none is written. Structural statements: ATP, adenosine bearing a 5'-triphosphate chain; N,N-dimethylphenethylamine, the constituent for which the extract is bought, a tertiary amine phenethylamine; L-carnitine, the (R) enantiomer; methionine, inositol and choline as set out on the Lipo-C fat BLASTER record; lidocaine, an aminoamide with a 2,6-dimethylanilide and a diethylaminoacetyl group; benzyl alcohol, a monosubstituted aromatic primary alcohol.

Molecular formula

Per component; a mixture has no combined formula and none is written, and for one component no formula exists at all. ATP C10H16N5O13P3 (disodium C10H14N5Na2O13P3; degradation products ADP C10H15N5O10P2 and AMP). N,N-dimethylphenethylamine C10H15N, as the marker constituent only - the extract itself has no formula, which is the record's central point. L-carnitine C7H15NO3. MIC components: C5H11NO2S, C6H12O6, C5H14ClNO. Lidocaine C14H22N2O (hydrochloride C14H23ClN2O; hydrochloride monohydrate adds one water). Benzyl alcohol C7H8O.

Average mass

Per component, on IUPAC 2021 abridged conventional atomic weights: ATP 507.181 (disodium 551.145; ADP 427.203); N,N-dimethylphenethylamine 149.237; L-carnitine 161.201; L-methionine 149.208; myo-inositol 180.156; choline chloride 139.623; lidocaine 234.343 (hydrochloride 270.801; hydrochloride monohydrate 288.816); benzyl alcohol 108.140. Worked example at a stated nominal per milliliter of ATP 20, extract 10, L-carnitine 200, methionine 25, inositol 50, choline 50, lidocaine 10 and benzyl alcohol 9 mg: 39.434, 67.008 as marker, 1,240.687, 167.551, 277.537, 358.107, 42.673 and 83.225 micromol. The extract figure is computed on the marker molecule and is fictitious as a component molarity, because an extract has no molar mass; it is shown to make that point rather than to be used. That composition is a stated nominal, not a market standard.

Monoisotopic mass

Per component, neutral: ATP 506.9957; N,N-dimethylphenethylamine 149.1204; L-carnitine 161.1052; L-methionine 149.0510; myo-inositol 180.0634; choline chloride 139.0764; lidocaine 234.1732; benzyl alcohol 108.0575. One collision is worth naming because it is an average-mass trap rather than A monoisotopic one: the extract's marker at 149.237 and methionine at 149.208 differ by 0.029 Da on average masses and by 0.069 Da monoisotopic, so nominal-mass or low-resolution detection cannot separate two components of this article and high-resolution acquisition is not optional.

Salt / variant note

(1) ratio: none standard. (2) the extract: no defined composition, no formula, no molar mass; marker content varies by lot and by supplier with nothing fixing it. (3) 'MIC': an abbreviation that must be expanded to methionine, inositol and choline, with the double-count against separately listed L-carnitine resolved in writing. (4) ATP salt and hydration: free acid 507.181 against disodium 551.145, with hydrates common and hygroscopic. (5) lidocaine salt: free base 234.343 against hydrochloride 270.801 against the hydrochloride monohydrate. (6) benzyl alcohol: an excipient rather than an active, at a level that is a formulation decision and a compendial limit.

2 Class & testing panel

Form

Fixed-ratio blend

Testing panel

P7 — panel definitionfor the Eria jarensis component, whose composition is undefined; that is a panel assignment and not a criticism. P6 for each of the defined small molecules. The panel runs per component and never once for the vial. A P7 component in a fixed-ratio article sets the panel for the article as a whole, and no analytical spend converts an extract of undeclared composition into a stated identity

3 Primary sources & evidence

The index reports the design and provenance of the literature, not a conclusion about effect.

Published literature exists for the individual defined components and is cross-referenced where a component record exists. The one publication that bears directly on this article is not about its performance but about its composition: Cohen and colleagues, Clinical Toxicology, 2025, doi 10.1080/15563650.2025.2515242, reporting that none of twelve products labeled as containing Eria jarensis was accurately labeled.

4 Storage & specification

Storage

Sealed, light-protected vials, stored cold at the temperature carried on the specification. Solution pH is controlled and carried on that specification as well, because ATP is hygroscopic as a solid and hydrolyzes in solution to ADP and inorganic phosphate, which makes pH and temperature control formulation requirements rather than shipping preferences; benzyl alcohol is volatile, so vials are kept closed and benzyl alcohol content is a stability attribute in its own right rather than a fixed formulation number.

Shelf life

The article is dated from the date of manufacture of the lot and carries the retest interval printed on its specification, which is set on the defined components and confirmed at each pull of the company's ICH-format stability program. What limits that interval is the extract: a stability-indicating method indicates against a known starting material, and the extract has no defined composition, so its contribution is held by marker content per lot rather than by an assay for the extract as a whole. The stability-indicating attributes are per-component content, the measured ratio, ADP and AMP, lidocaine related compounds, benzyl alcohol content, pH and any new peak above 0.10 percent.